IONIQ Sciences 2021 Year-End Update

February 10, 2022

Originally published by IONIQ Sciences

Dear IONIQ Sciences Shareholders and Friends,

Greetings from IONIQ Sciences where we continue to follow the science and invest in exceptional team members, advisors and consultants to help us modernize early-stage cancer detection. 

LUNG Cancer – we have submitted our application to the FDA!!

• We have formally submitted our De Novo application to the FDA seeking marketing clearance in the USA for our ‘breakthrough device‘ in lung cancer. 
• We appreciate all of the expert input and feedback from our many regulatory consultants and partners. 
• Our application is now in the hands of the FDA to review and evaluate. We anticipate that it will be months before the FDA engages us with questions and/or additional data requests. 

Expanding our growing LUNG cancer clinical evidence library

• We have been conducting a lung cancer pilot clinical study in the USA since mid-2021 with the goal of expanding our growing clinical evidence library. 
• We are making final preparations to transition this trial into a clinical validation study. Follow this link to view a list of currently participating sites. 

Expanding into BREAST Cancer – life-saving potential published in IEEE scientific journal

• We have been conducting a clinical feasibility trial in breast cancer since 2020. 
• This work culminated in the Nov 2021 publication of a scientific manuscript in the prestigious IEEE Access peer-reviewed journal that detailed the life-saving potential of our bioimpedance technology in breast cancer. Click here to read our scientific manuscript. 
• We aim to to expand our breast cancer clinical work this year to unleash the power of our platform into multiple cancers.

INTELLECTUAL PROPERTY – portfolio continues to grow

• We added 2 more patents to our patent portfolio bringing our total to 7 owned patents, 4 licensed and 5 applications. 

RECOGNITION – awareness of our accomplishments continues to grow

• We added 4 more awards to our trophy case in 2021.
• We were highlighted another 5 times by patient advocacy groups and news outlets. 
• We sent out 11 email updates through the year. Click here to see all our news! 

TEAM – strategically adding exceptional individuals to help us accelerate and expand

• IONIQ has an agile, passionate and talented Team, Board, Advisors and Consultants with a shared vision to modernize early-stage cancer detection. During 2021, we strategically grew our team by ~30% to help make our vision a reality.
• Added Dr. Raphael Pollock, Director of The Ohio State University Comprehensive Cancer Center, to our Medical Advisory Committee. Dr. Pollock is an award-winning physician and PhD scientist who is helping us expand into other cancers.
• Added Dr. Benjamin Haibe-Kains, Senior PhD Scientist at Princess Margaret Cancer Centre, to our Scientific Advisory Committee. Dr. Haibe-Kains has extensive scientific and oncology experience developing new prognostic and predictive models that is helping us develop additional single cancer Tests and ultimately a Multi-Cancer Screen. 
• Promoted Natasha Andreasen to Clinical Coordinator. With her clinical background, Ms. Andreasen has been instrumental in starting-up and training our growing number of clinical trial sites. She is also our lead operator here in the office.
• Hired Kyle Larsen as Research Scientist. Mr. Larsen, PhD candidate, joined our R&D team to accelerate the development of the next-generation of our device. We envision our product moving from hospitals and doctor’s offices to pharmacies and ultimately to your home. 
• Appointed Aaron B. Dorny to our Board of Directors. Mr. Dorny’s deep understanding of our business and proven financial acumen have increased IONIQ’s market readiness and institutional attractiveness. 

Institutional fundraising

• We continue to thoughtfully evaluate potential life science and strategic partners to join us in modernizing early-stage cancer detection. 

How can you help IONIQ Sciences? Please help us identify people in the SLC-area to scan for approximately 40 minutes. 

• Healthy subjects across ethnicities.
• Subjects with lung, breast and/or other cancers.
• Financial compensation can be provided to subjects.
• Please contact Mike Garff, IONIQ COO at mag@IONIQsciences.com or 385-501-7002.

Nothing in this email constitutes an offer to buy, or a solicitation of an offer to sell, securities in the United States or any other jurisdiction in which such offer or solicitation would be unlawful. This email is being issued pursuant to and in accordance with Rule 135c under the Securities Act. Please refer to the Company’s latest SEC filings for risk factors, disclosures and forward looking statements. Product is not available for sale in the USA. 

We invite you to follow us on social media where we share updates. Links to our corporate pages can be found at the bottom of this email (@IONIQsciences).